Skip to main content

Table 1 Genomic coordinates of ERE-like sequences that have been experimentally validated or rejected as ER-binding

From: Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding sites

Name Genomic location Pattern Validation Reference
PDZK1 chr1:143,215,756-143,215,768 GGTCAcccAGTCC Binding This study
ADORA1 chr1:199,790,269-199,790,281 GGTTAgggTGACC Binding [10] and this study
ADORA1 chr1:199,790,414-199,790,426 GGTGTcttTGACC Binding This study
AGT chr1:227,156,613-227,156,625 GGGCAtcgTGACC Binding [4]
GREB1 chr2:11,603,634-11,603,646 GGTCAaaaTGACC Binding [10]
GREB1 chr2:11,615,324-11,615,336 GGTCAtcaTGACC Binding [10]
GREB1 chr2:11,621,861-11,621,873 AGTCAgtgTCACC Binding This study
GREB1 chr2:11,623,258-11,623,270 GGTCAttcTGACC Binding [8,10]
CYP1B1 chr2:38,214,993-38,215,005 GGTCGcgcTGCCC Binding This study
CYP1B1 chr2:38,215,049-38,215,061 GGTCAaagCGGCC Binding This study
LTF chr3:46,481,739-46,481,751 GGTCAaggCGATC Binding [10]
AREG chr4:75,676,340-75,676,352 GGACAaggTGTCC Binding This study
ELOVL2 chr6:11,154,748-11,154,760 GGTCAtctTGATG Binding This study
VEGF chr6:43,844,381-43,844,393 AATCAgacTGACT Binding [4]
LY6E chr8:144,170,802-144,170,814 GGACAagaTGACC Binding [10]
PTGES chr9:129,597,654-129,597,666 GGACAgccTGGCC Binding This study
CASP7 chr10:115,428,398-115,428,410 GGTCAgggTGAAC Binding [10]
CASP7 chr10:115,428,492-115,428,504 GGTCGgggTGAAC Binding [10]
CASP7 chr10:115,428,572-115,428,584 GGTCAgggTGAAC Binding [10]
CASP7 chr10:115,428,612-115,428,624 GGTCAgggTGAAC Binding [10]
CASP7 chr10:115,428,652-115,428,664 GGTCAgggTGAAC Binding [10]
CASP7 chr10:115,428,689-115,428,701 GGTCAgggTGAAC Binding [10]
CASP7 chr10:115,428,743-115,428,755 GGTCAgggTGAAC Binding [10]
CTSD chr11:1,741,924-1,741,936 GGCCGggcTGACC Binding [4]
PGR chr11:100,504,595-100,504,607 GGTCAccaGCTCT Binding [4]
PGR chr11:100,505,180-100,505,192 GCAGGagcTGACC Binding [4]
SCNN1A chr12:6,355,536-6,355,548 GGTCAgccTCACC Binding [10]
GAPDH chr12:6,513,208-6,513,220 GGACAtcgTGACC Binding [10]
ESR2 chr14:63,879,248-63,879,260 GGTCAggcTGGTC Binding [4]
FLJ30973 chr15:55,670,850-55,670,862 GGGCAgtgTGGCC Binding This study
FLJ30973 chr15:55,671,545-55,671,557 GGTCAcccTGCTC Binding This study
ABCA3 chr16:2,319,793-2,319,805 GGTCAcggTGTTC Binding [8]
IGFBP4 chr17:35,849,113-35,849,125 GGTCAttgTGACA Binding [10]
TRIM25 chr17:52,323,321-52,323,333 GGTCAtggTGACC Binding [4], [10]
BCL2 chr18:59,136,673-59,136,685 GGTCGccaGGACC Binding [4]
MGC26694 chr19:19,035,118-19,035,130 GTTCAgagTGACC Binding This study
GRAMD1A chr19:40,182,519-40,182,531 GGCCTggcTGACC Binding This study
ACTN4 chr19:43,897,093-43,897,105 GGTCActgTGACT Binding This study
GPR77 chr19:52,532,131-52,532,143 GGTCActcTGACA Binding This study
C3 chr19:6,671,884-6,671,902 GGTGGcccTGACC Binding [4]
NRIP1 chr21:15,359,833-15,359,845 GGTCAaagTGACC Binding [8]
TFF1 chr21:42,659,626-42,659,638 GGTCCtggTGTCC Binding This study
TFF1 chr21:42,659,906-42,659,918 AGCCAagaTGACC Binding This study
TFF1 chr21:42,660,106-42,660,118 GGTCAcggTGGCC Binding [4]
CRKL chr22:19,595,695-19,595,707 AGTCAatcTAACC Binding This study
TSHB chr1:115,283,928-115,283,940 GGTCAgctTGACA Nonbinding [10]
TXNIP chr1:142,927,222-142,927,234 GGTCAgtgGGATC Nonbinding This study
LOR chr1:150,045,850-150,045,862 GGTCCaaaGGACC Nonbinding This study
GREB1 chr2:11,622,443-11,622,455 TGCCAccaTGACC Nonbinding This study
GREB1 chr2:11,625,143-11,625,155 TGTCAatcTGTCC Nonbinding This study
EN1 chr2:119,322,563-119,322,575 GGTTAcccTGAAC Nonbinding This study
UGCGL1 chr2:128,563,200-128,563,212 TGTCAaaaTGTCC Nonbinding This study
UGCGL1 chr2:128,565,292-128,565,304 TGTCAcatTGAGC Nonbinding This study
PLGLB1 chr2:87,884,778-87,884,790 GGTCAgtgTGCCA Nonbinding This study
SIAH2 chr3:151,966,545-151,966,557 GCTCAtagTGCCC Nonbinding This study
ATP13A3 chr3:195,656,453-195,656,465 GGTCAttaATACC Nonbinding This study
CISH chr3:50,626,609-50,626,621 GGCCAgagGGACC Nonbinding This study
LMCD1 chr3:8,517,591-8,517,603 GGCCTgcaTGACC Nonbinding This study
FLJ22269 chr4:673,249-673,261 GGGCAgagTGACT Nonbinding This study
CCNG2 chr4:78,433,176-78,433,188 GGACAactTGATC Nonbinding This study
STC2 chr5:172,689,912-172,689,924 GGGCAatgTGAAC Nonbinding This study
IL6ST chr5:55,327,909-55,327,921 GGTGAgcaTGATC Nonbinding This study
PLK2 chr5:57,792,972-57,792,984 GGTTAcagCGACC Nonbinding This study
OLIG3 chr6:137,857,308-137,857,320 CGTCAtccTAACC Nonbinding This study
FKBPL chr6:32,206,228-32,206,240 GGCCAgccCGACC Nonbinding This study
FKBPL chr6:32,206,311-32,206,323 CGCCAccaTGACC Nonbinding This study
SERPINE1 chr7:100,361,980-100,361,992 GACCAgccTGACC Nonbinding This study
SERPINE1 chr7:100,362,938-100,362,950 GGACAagcTGCCC Nonbinding This study
SERPINE1 chr7:100,363,852-100,363,864 TGTCAagaAGACC Nonbinding This study
TSPAN13 chr7:16,566,080-16,566,092 GATAAgtcTGACC Nonbinding This study
BLVRA chr7:43,570,289-43,570,301 GGTCActcTGGCT Nonbinding This study
BLVRA chr7:43,570,774-43,570,786 AGTCAaccTTACC Nonbinding This study
B4GALT1 chr9:33,157,593-33,157,605 GCTCAacgCGACC Nonbinding This study
B4GALT1 chr9:33,158,622-33,158,634 GATCAgaaGGACC Nonbinding This study
DNAJC1 chr10:22,333,030-22,333,042 GTTCAactTGTCC Nonbinding This study
GAD2 chr10:26,545,037-26,545,049 GGTCGcagTGACC Nonbinding [10]
CXCL12 chr10:44,202,437-44,202,449 GGTCCagcTGCCC Nonbinding This study
CXCL12 chr10:44,203,283-44,203,295 TGTCAaaaTGGCC Nonbinding This study
PGR chr11:100,509,203-100,509,215 AGTCAtgtTGACA Nonbinding This study
DGKZ chr11:46,321,832-46,321,844 GGCCAtgcTGGCC Nonbinding This study
CTSW chr11:65,403,499-65,403,511 GACCAgccTGACC Nonbinding This study
C14orf131 chr14:101,872,078-101,872,090 GGCCAacaTGACA Nonbinding This study
DLG7 chr14:54,727,987-54,727,999 GGTCGtccAGACC Nonbinding This study
ESR2 chr14:63,876,354-63,876,366 GACCAgccTGACC Nonbinding This study
THBS1 chr15:37,657,943-37,657,955 GGTCAatcCCACC Nonbinding This study
FLJ13710 chr15:69,737,514-69,737,526 AGTCAttgTTACC Nonbinding This study
FLJ13710 chr15:69,738,257-69,738,269 GGTCAatgTGCGC Nonbinding This study
FLJ13710 chr15:69,738,459-69,738,471 GCTCActtTGTCC Nonbinding This study
SH3GL3 chr15:82,077,053-82,077,065 GATCTtgcTGACC Nonbinding This study
SMAP-1 chr15:89,278,745-89,278,757 AGTCAatcTGTCC Nonbinding This study
ABCA3 chr16:2,321,166-2,321,178 GGTCTtttTTACC Nonbinding This study
HCFC1R1 chr16:3,015,149-3,015,161 GACCAgccTGACC Nonbinding This study
ADCY9 chr16:4,107,737-4,107,749 GGTCAggcTGGTC Nonbinding This study
ADCY9 chr16:4,108,935-4,108,947 GGTGAaaaTGTCC Nonbinding This study
CAPNS2 chr16:54,100,244-54,100,256 GGTCCgtcCGACC Nonbinding This study
PAFAH1B1 chr17:2,441,502-2,441,514 CGCCAtgtTGACC Nonbinding This study
IGFBP4 chr17:35,851,519-35,851,531 GATCActgTAACC Nonbinding This study
IGFBP4 chr17:35,853,510-35,853,522 GGTCAtgcTGCCC Nonbinding This study
RBBP8 chr18:18,766,140-18,766,152 GGTCAttcTGCTC Nonbinding This study
MKNK2 chr19:2,382,491-2,382,503 GGGCAgagTGAGC Nonbinding This study
BBC3 chr19:52,426,840-52,426,852 TGTCAttgTGTCC Nonbinding This study
BBC3 chr19:52,427,249-52,427,261 GGTCAggcTGGTC Nonbinding This study
GPBP6 chrY:169,893-169,905 GCTCAcgaTGACG Nonbinding This study
  1. Shown in bold and underlined are nucleotides that deviate from the consensus core ERE. ER, estrogen receptor; ERE, estrogen response element.